Back to Search
Start Over
Baseline CSF/Serum-Ratio of Apolipoprotein E and Rate of Differential Decline in Alzheimer’s Disease
- Source :
- Journal of Alzheimer's disease 48(1), 189-196 (2015). doi:10.3233/JAD-150286
- Publication Year :
- 2015
- Publisher :
- IOS Press, 2015.
-
Abstract
- Background/Objective: Apolipoprotein E (ApoE) has an active part in the pathogenesis of Alzheimer’s disease (AD). Cerebrospinal fluid (CSF) and plasma level alterations have been reported in AD patients. In search of a biomarker potentially predictive of cognitive, functional, or motor decline, we analyzed the CSF to serum ratios of ApoE levels (CSF/serum ApoE) in AD patients in this regard. Methods: Subjects with newly diagnosed AD were followed within a longitudinal observational study (rpAD study). Annual neuropsychological testing and physical examination were performed. Multiple regression analyses were used to determine possible associations of the ApoE CSF/serum concentration ratios and velocity of decline on a variety of cognitive, functional and motor scales (MMSE, iADL, bADL, GDS, UPDRSIII) adjusted for relevant co-variables. Results: CSF/serum ratios of ApoE levels were associated with progression on the UPDRSIII (change of UPDRSIII slope [pt/yr] per unit of ApoE CSF/serum = –0.06, p < 0.01) and instrumental ADL scale (change of iADL slope [pt/yr] per unit of ApoE CSF/serum = 0.01, p = 0.01) (“the lower the ratio, the faster the deterioration” and vice versa). Secondarily, higher age at onset was associated with faster UPDRSIII progression, antidepressant use with faster iADL decline, and better baseline function with more rapid decline on either MMSE, iADL, or GDS scale. Conclusion: Here, CSF/serum ApoE at time of AD diagnosis was shown to be inversely associated with medium-term functional and motor progression. Whether this ratio qualifies for the use as a predictive biomarker must be validated in larger cohort studies over the long term.
- Subjects :
- Male
Apolipoprotein E
Gerontology
Movement disorders
cerebrospinal fluid [Amyloid beta-Peptides]
Severity of Illness Index
Gastroenterology
Pathogenesis
0302 clinical medicine
Cerebrospinal fluid
Longitudinal Studies
0303 health sciences
Movement Disorders
etiology [Movement Disorders]
General Neuroscience
complications [Alzheimer Disease]
General Medicine
Middle Aged
amyloid beta-protein (1-42)
cerebrospinal fluid [Cognition Disorders]
3. Good health
blood [Apolipoproteins E]
Psychiatry and Mental health
Clinical Psychology
cerebrospinal fluid [Movement Disorders]
Biomarker (medicine)
Female
Alzheimer's disease
medicine.symptom
Psychology
Cohort study
medicine.medical_specialty
tau Proteins
cerebrospinal fluid [Apolipoproteins E]
03 medical and health sciences
Apolipoproteins E
Alzheimer Disease
Internal medicine
Severity of illness
medicine
Humans
blood [Movement Disorders]
ddc:610
cerebrospinal fluid [Peptide Fragments]
Aged
030304 developmental biology
Amyloid beta-Peptides
etiology [Cognition Disorders]
amyloid beta-protein (1-40)
medicine.disease
Peptide Fragments
cerebrospinal fluid [tau Proteins]
Geriatrics and Gerontology
Cognition Disorders
Mental Status Schedule
human activities
blood [Cognition Disorders]
030217 neurology & neurosurgery
Subjects
Details
- ISSN :
- 18758908 and 13872877
- Volume :
- 48
- Database :
- OpenAIRE
- Journal :
- Journal of Alzheimer's Disease
- Accession number :
- edsair.doi.dedup.....3e02cc8f99ea476729b9e1026bc7e963